{"clinical_study": {"@rank": "136", "required_header": {"download_date": "ClinicalTrials.gov processed this data on April 02, 2020", "link_text": "Link to the current ClinicalTrials.gov record.", "url": "https://clinicaltrials.gov/show/NCT04311177"}, "id_info": {"org_study_id": "SURG-2020-28683", "nct_id": "NCT04311177"}, "brief_title": "Losartan for Patients With COVID-19 Not Requiring Hospitalization", "official_title": "Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization", "sponsors": {"lead_sponsor": {"agency": "University of Minnesota", "agency_class": "Other"}}, "source": "University of Minnesota", "oversight_info": {"has_dmc": "Yes", "is_fda_regulated_drug": "Yes", "is_fda_regulated_device": "No", "is_us_export": "No"}, "brief_summary": {"textblock": "This is a multi-center, double-blinded study of COVID-19 infected patients randomized 1:1 to\n      daily losartan or placebo for 10 days or treatment failure (hospital admission)."}, "overall_status": "Not yet recruiting", "start_date": {"@type": "Anticipated", "#text": "March 16, 2020"}, "completion_date": {"@type": "Anticipated", "#text": "April 1, 2021"}, "primary_completion_date": {"@type": "Anticipated", "#text": "April 1, 2021"}, "phase": "Phase 2", "study_type": "Interventional", "has_expanded_access": "No", "study_design_info": {"allocation": "Randomized", "intervention_model": "Parallel Assignment", "primary_purpose": "Treatment", "masking": "Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)"}, "primary_outcome": {"measure": "Hospital Admission", "time_frame": "28 days", "description": "Outcome reported as the number of participants per arm admitted to inpatient hospital care due to COVID-19-related disease."}, "secondary_outcome": [{"measure": "Change in PROMIS Dyspnea Functional Limitations", "time_frame": "baseline, 10 days", "description": "The PROMIS Dyspnea (shortness of breath) item banks and pools assess self-reported Functional Limitations, Severity, Activity Motivation, Activity Requirements, Airborne Exposure, Assistant Devices Resources, Characteristics, Emotional Response, Task Avoidance and Time Extension as they related to dyspnea.\nIn the 33-item Functional Limitations bank, 33 daily activities are rated in terms of degree of difficulty while engaging in the activity over the past 7 days (0 = no difficulty, 1 = a little difficulty, 2 = some difficulty, 3 = much difficulty). Total scores range from 0 to 99, with higher scores reflecting greater functional limitations."}, {"measure": "Change in PROMIS Dyspnea Severity", "time_frame": "baseline, 10 days", "description": "The PROMIS Dyspnea (shortness of breath) item banks and pools assess self-reported Functional Limitations, Severity, Activity Motivation, Activity Requirements, Airborne Exposure, Assistant Devices Resources, Characteristics, Emotional Response, Task Avoidance and Time Extension as they related to dyspnea.\nThe 33-item Severity bank assesses the severity of difficulty breathing during various specific activities (the same 33 activities assessed in Dyspnea Functional Limitations). Each activity is rated in terms of degree of dyspnea (0 = no shortness of breath, 1 = mildly short of breath, 2 = moderately short of breath, 3 = severely short of breath) while engaging in the activity over the past 7 days. Total scores range from 0 to 99 with higher scores reflecting greater levels of dyspnea during daily activity."}, {"measure": "Fever Incidence Day 3", "time_frame": "10 days", "description": "Participants will record oral temperature every day for 10 days. Outcome is reported as body temperature (in degrees Celsius) at day 3."}, {"measure": "Fever Incidence Day 5", "time_frame": "10 days", "description": "Participants will record oral temperature every day for 10 days. Outcome is reported as body temperature (in degrees Celsius) at day 5."}, {"measure": "Fever Incidence Day 7", "time_frame": "10 days", "description": "Participants will record oral temperature every day for 10 days. Outcome is reported as body temperature (in degrees Celsius) at day 7."}, {"measure": "Fever Incidence Day 10", "time_frame": "10 days", "description": "Participants will record oral temperature every day for 10 days. Outcome is reported as body temperature (in degrees Celsius) at day 10."}, {"measure": "Severity of Symptoms upon Hospital Admission", "time_frame": "28 days", "description": "Outcome is reported as the number of participants in each arm who are admitted to inpatient hospital care and who present with organ failure (as determined by physician) at the time of admission."}], "number_of_arms": "2", "enrollment": {"@type": "Anticipated", "#text": "516"}, "condition": ["Corona Virus Infection", "Acute Respiratory Distress Syndrome", "SARS-CoV Infection"], "arm_group": [{"arm_group_label": "Losartan", "arm_group_type": "Experimental", "description": "Participants in this arm will receive the study drug, Losartan."}, {"arm_group_label": "Placebo", "arm_group_type": "Placebo Comparator", "description": "Participants in this arm will receive a placebo treatment."}], "intervention": [{"intervention_type": "Drug", "intervention_name": "Losartan", "description": "Losartan; 25 mg daily; oral administration", "arm_group_label": "Losartan", "other_name": "Cozaar"}, {"intervention_type": "Other", "intervention_name": "Placebo", "description": "Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration", "arm_group_label": "Placebo"}], "eligibility": {"criteria": {"textblock": "Inclusion Criteria:\n\n          -  Presumptive positive laboratory test for SARS-CoV-2 or upper respiratory infection\n             with recent exposure to laboratory-proven SARS-CoV-2-infected person\n\n          -  Negative influenza and respiratory virus panel\n\n          -  Randomization within 48 hours of meeting inclusion criteria\n\n        Exclusion Criteria:\n\n          -  Currently taking an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin\n             receptor blocker (ARB)\n\n          -  Prior reaction or intolerance to an ARB or ACEi\n\n          -  Potassium great than 5.0 mEq/L within 4 weeks of study enrollment\n\n          -  Pregnancy or breastfeeding\n\n          -  Females of childbearing age\n\n          -  Estimated Glomerular Filtration Rate (eGFR) of < 30ml/min/1.73 m2 within 4 weeks of\n             study initiation or history of advanced renal disease\n\n          -  AST and/or ALT > 3 times the upper limit of normal within 4 weeks of study enrollment\n\n          -  Concurrent treatment with Alikirin\n\n          -  Inability to obtain informed consent\n\n          -  Non-English speakers"}, "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No"}, "overall_official": [{"last_name": "Christopher Tignanelli, MD", "role": "Principal Investigator", "affiliation": "University of Minnesota"}, {"last_name": "Michael Puskarich, MD, MS", "role": "Principal Investigator", "affiliation": "University of Minnesota"}], "overall_contact": {"last_name": "Christopher Tignanelli, MD", "phone": "612-625-7911", "email": "ctignane@umn.edu"}, "overall_contact_backup": {"last_name": "Michael Puskarich, MD, MS", "phone": "612-626-6911", "email": "mike-em@umn.edu"}, "location": [{"facility": {"name": "Hennepin County Medical Center", "address": {"city": "Minneapolis", "state": "Minnesota", "zip": "55415", "country": "United States"}}}, {"facility": {"name": "M Health Fairview University of Minnesota Medical Center", "address": {"city": "Minneapolis", "state": "Minnesota", "zip": "55455", "country": "United States"}}, "investigator": [{"last_name": "Jeffrey Chipman, MD", "role": "Sub-Investigator"}, {"last_name": "Ron Reikoff, MD", "role": "Sub-Investigator"}]}, {"facility": {"name": "University of Minnesota", "address": {"city": "Minneapolis", "state": "Minnesota", "zip": "55455", "country": "United States"}}, "investigator": [{"last_name": "Timothy Schacker, MD", "role": "Sub-Investigator"}, {"last_name": "Nicholas Ingraham, MD", "role": "Sub-Investigator"}, {"last_name": "David Wacker, MD", "role": "Sub-Investigator"}, {"last_name": "Michelle Biros, MD, MS", "role": "Sub-Investigator"}]}], "location_countries": {"country": "United States"}, "verification_date": "March 2020", "study_first_submitted": "March 13, 2020", "study_first_submitted_qc": "March 13, 2020", "study_first_posted": {"@type": "Actual", "#text": "March 17, 2020"}, "last_update_submitted": "March 19, 2020", "last_update_submitted_qc": "March 19, 2020", "last_update_posted": {"@type": "Actual", "#text": "March 23, 2020"}, "responsible_party": {"responsible_party_type": "Sponsor"}, "keyword": ["COVID-19", "Corona Virus", "SARS-COV-2"], "condition_browse": {"mesh_term": ["Infection", "Communicable Diseases", "Coronavirus Infections", "Severe Acute Respiratory Syndrome", "Respiratory Distress Syndrome, Newborn", "Respiratory Distress Syndrome, Adult", "Acute Lung Injury"]}, "intervention_browse": {"mesh_term": "Losartan"}, "patient_data": {"sharing_ipd": "No"}}}